Related Experiment Video
Updated: Jun 28, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors
Insights
Experts discussed challenges in diagnosing, evaluating, treating, and managing clustered cardiometabolic risk factors. Addressing these complex conditions requires a comprehensive approach for better patient outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- A panel convened to address the multifaceted challenges in the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors.
- Cardiometabolic risk factors, when clustered, present significant diagnostic and therapeutic hurdles.
Discussion:
- The panel explored current strategies and identified gaps in managing patients with multiple cardiometabolic risk factors.
- Key challenges include the accurate assessment of individual risk, patient adherence to treatment, and the integration of various therapeutic interventions.
Key Insights:
- Effective management necessitates a holistic approach, considering the interplay between different risk factors.
- Improved diagnostic tools and patient-centered treatment plans are crucial for optimizing outcomes.
Outlook:
- Future efforts should focus on developing integrated care models and innovative therapeutic strategies.
- Continued research is needed to refine risk stratification and personalize treatment for cardiometabolic disorders.
Abstract:
A panel was convened on February 18, 2008, to discuss the challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. Peter W.F. Wilson, MD of Emory University School of Medicine, Atlanta, GA, moderated the panel. Henry R. Black, MD, New York University School of Medicine, New York, NY, Anthony N. Fabricatore, PhD, University of Pennsylvania, Philadelphia, PA, and Ira J. Goldberg, MD, Columbia University, New York, NY, participated in the discussion. This expert panel discussion was supported by and each author received an honorarium from Pfizer Inc for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content before publication. The authors maintained full control of the discussion and the resulting content of this article.
Related Concept Videos
Coronary Artery Disease I: Introduction
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Type II Diabetes I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy